BCAA and vitamin D administration on sarcopenia and bone metabolism abnormality in cirrhosis patients

Not Applicable

• Conditions: cirrhosis; cirrhosis sarcopenia; D008103

• Registration Number: JPRN-jRCTs031180428
• Lead Sponsor: Okubo Tomomi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-26
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Decompensated cirrhosis with hypoalbuminemia

Exclusion Criteria

Patient with inborn branch chain amino acid metabolic derangement
Hepatic encephalopathy more than 3
Total bilirubin value >3 mg/dl
patien with decrease of the protein composition ability in the liver
The patient allergic to milk
The patient who has the medical history of the hyperesthesia to BCAA medicine
The patient who is nursing and pregnant
Patient with uncotrolled HCC or other malignant tumor
Uncontrolled heart failure patient
Uncontrolled hypertension or diabetes
Patient with Chronic renal failure
Patient of hypercalcemia
Patient with hyperthyroidism
Patient who already takes other vitamin D Patien who takes the drug that combination with the vitamin D preparation is contraindicated
Patient with acute liver failure
Patient who were judged unsuitable by test responsibility doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified